PMID- 26539624 OWN - NLM STAT- MEDLINE DCOM- 20160916 LR - 20190109 IS - 1557-7732 (Electronic) IS - 1080-7683 (Print) IS - 1080-7683 (Linking) VI - 31 IP - 10 DP - 2015 Dec TI - Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. PG - 589-604 LID - 10.1089/jop.2015.0064 [doi] AB - This article reviews ocular adverse events (AEs) reported in association with administration of antibody-drug conjugates (ADCs) in human clinical trials. References reporting ocular toxicity or AEs associated with ADCs were collected using online publication searches. Articles, abstracts, or citations were included if they cited ocular toxicities or vision-impairing AEs with a confirmed or suspected association with ADC administration. Twenty-two references were found citing ocular or vision-impairing AEs in association with ADC administration. All references reported use of ADCs in human clinical trials for treatment of various malignancies. The molecular target and cytotoxic agent varied depending on the ADC used. Ocular AEs affected a diversity of ocular tissues. The most commonly reported AEs involved the ocular surface and included blurred vision, dry eye, and corneal abnormalities (including microcystic corneal disease). Most ocular AEs were not severe (